Balazs Halmos, Professor of Medicine at Montefiore Health System, shared NEJM’s post on X, adding:
“Great paper on benefit of Tam-peli easily beating SOC topotecan in 2nd line ES-SCLC. But wrong figures attached by NEJM on sac-TMT. Now fixed it!
Excellent data by Dr Zhao and et al can hardly wait to see one of these agents approved as study also shows sobering new reality for us- w tarla moving into maintenance and lurbi ‘ousted’, are we supposed to go back to topote can’t.
With pitiful data as seen in this study: 60% of pts progress on topo by 3 months, ORR<10% and with grade 3 or higher AEs at 75%! And very burdensome schedule i just can’t. And our patients shouldn’t.”
NEJM shared:
“Title: Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy
Authors: Yuanyuan Zhao, Hongxu Liu, Xiangjiao Meng, Zhihua Liu, Yan Yu, Yulong Zheng, Longhua Sun, Runxiang Yang, Jian Liu, Yanqiu Zhao, Lin Wu, Lei Yang, Zhiye Zhang, Mingjun Li, Peng Zhang, Yan Zhang, Hua Zhong, Jiuwei Cui, Zhangzhou Huang, Yanwei Yin, Manxiang Li, Fan Tong, Dan Xue, Dongqing Lv, Xufeng Li, Xian Zhang, Steve Chin, Jiaqiang Cai, Tongtong Xue, Yan Huang, Hongyun Zhao, Li Zhang
This can be interesting:
